[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564382":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":140,"collaborators":143,"id":149,"slug":150,"hasResults":151,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":151,"sex":157,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":18,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous Glucose Monitoring","EXPERIMENTAL","Real-time continuous glucose monitoring",[13],"Device: CGM",{"label":15,"type":16,"description":17,"interventionNames":18},"Self-Monitoring of Blood Glucose","NO_INTERVENTION","Self-monitoring of blood glucose (standard of care)",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"DEVICE","CGM",[9],[25],{"name":26,"affiliation":5,"role":27},"Ashley Battarbee, MD, MSCR","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","205-975-2361","anbattarbee@uabmc.edu",[34,50,65,80,95,110,125],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-86.80249,33.52066,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":31,"phoneExt":18,"email":32},"Ashley Battarbee",{"facility":51,"status":35,"city":52,"state":53,"zip":54,"country":39,"countryCode":40,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"University of California at San Diego","San Diego","California","92121",{"type":42,"coordinates":56},[57,58],-117.16472,32.71571,{"lat":58,"lon":57},[61],{"name":62,"role":30,"phone":63,"phoneExt":18,"email":64},"Gladys Ramos, MD","858-657-7200","gramos@health.ucsd.edu",{"facility":66,"status":35,"city":67,"state":68,"zip":69,"country":39,"countryCode":40,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"University of North Carolina - Chapel Hill","Chapel Hill","North Carolina","27599",{"type":42,"coordinates":71},[72,73],-79.05584,35.9132,{"lat":73,"lon":72},[76],{"name":77,"role":30,"phone":78,"phoneExt":18,"email":79},"Kim Boggess, MD","919-966-2131","kim_boggess@med.unc.edu",{"facility":81,"status":35,"city":82,"state":83,"zip":84,"country":39,"countryCode":40,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Oregon Health and Science University","Portland","Oregon","97213",{"type":42,"coordinates":86},[87,88],-122.67621,45.52345,{"lat":88,"lon":87},[91],{"name":92,"role":30,"phone":93,"phoneExt":18,"email":94},"Amy Valent, DO, MCR","503-418-4200","valent@ohsu.edu",{"facility":96,"status":35,"city":97,"state":98,"zip":99,"country":39,"countryCode":40,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":42,"coordinates":101},[102,103],-75.16362,39.95238,{"lat":103,"lon":102},[106],{"name":107,"role":30,"phone":108,"phoneExt":18,"email":109},"Celeste Durnwald, MD","800-789-7366","celeste.durnwald@pennmedicine.upenn.edu",{"facility":111,"status":35,"city":112,"state":113,"zip":114,"country":39,"countryCode":40,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Prisma Health Greenville Memorial Hospital","Greenville","South Carolina","29605",{"type":42,"coordinates":116},[117,118],-82.39401,34.85262,{"lat":118,"lon":117},[121],{"name":122,"role":30,"phone":123,"phoneExt":18,"email":124},"Daniel Pasko, MD","864-455-7000","daniel.pasko@prismahealth.org",{"facility":126,"status":35,"city":127,"state":128,"zip":129,"country":39,"countryCode":40,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"University of Texas Health Science Center at Houston","Houston","Texas","77030",{"type":42,"coordinates":131},[132,133],-95.36327,29.76328,{"lat":133,"lon":132},[136],{"name":137,"role":30,"phone":138,"phoneExt":18,"email":139},"Michal Fishel Bartal, MD","832-325-7133","michal.f.bartal@uth.tmc.edu",{"type":27,"investigatorFullName":141,"investigatorTitle":142,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Ashley N. Battarbee","Associate Professor",[144,147],{"name":145,"class":146},"National Institutes of Health (NIH)","NIH",{"name":148,"class":146},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","100564382","cgm-for-management-of-type-2-diabetes-in-pregnancy-100564382",false,"NCT06628453","CGM for Management of Type 2 Diabetes in Pregnancy","Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy","CGM2","Inclusion Criteria:\n\n* Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater\n* Pregnant with viable fetus at 6 to less than 23 weeks gestation\n* Maternal age 18-50 years old\n\nExclusion Criteria:\n\n* Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions\n* Multiple gestation\n* Major fetal anomaly or two or more minor fetal anomalies\n* Planned delivery outside study consortium\n* Participating in another conflicting interventional study\n* Participation in this trial in a previous pregnancy\n* Patient unable to consent\n* Physician refusal for other reasons","FEMALE","18 Years","50 Years",{"count":161,"type":162},564,"ESTIMATED","INTERVENTIONAL",[165],"NA","The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are:\n\n1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose?\n2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose?\n3. What other factors increase the risk of maternal and infant complications?\n\nParticipants will:\n\n1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery\n2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis\n3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits\n4. Have umbilical cord blood collected at delivery for analysis",[168,169],"Type 2 Diabetes Mellitus (T2DM)","Pregnancy",[171,169,22],"Diabetes","2026-06-24",{"date":174,"type":175},"2026-06-29","ACTUAL",{"date":177,"type":175},"2025-04-08",{"date":179,"type":162},"2029-07",{"name":5,"class":6},7]